ArticleVirchows Archiv : an international journal of pathology2026
Clinicopathological correlations and immunohistochemical expression of ATRX and Rb in soft tissue leiomyosarcoma: Insights into tumor features and prognostic stratification.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue leiomyosarcoma (STLMS) remains a challenging malignancy with variable clinical outcomes, highlighting the need for reliable prognostic biomarkers. Recent genomic studies have proposed risk stratification models based on RB1 and ATRX alterations; however, the utility of corresponding immunohistochemical (IHC) surrogates has not been fully explored. In this study, we analyzed clinicopathological features and ATRX/Rb IHC expression in a cohort of 70 STLMS cases to identify correlates of aggressive behavior and assess their prognostic value. Metastasis was significantly associated with female sex (p = 0.004), age ≤ 60 years (p = 0.022), internal cavity location (p = 0.014), necrosis (p = 0.032), elevated mitotic rate (p = 0.01), high FNCLCC grade (p < 0.001), larger tumor size (p = 0.03), and deep/internal origin. Loss of ATRX staining (44% of cases) correlated significantly with larger tumor size (p = 0.003), deep location (p = 0.015), and internal cavity site (p = 0.007), linking ATRX deficiency to more extensive local disease. Rb loss was frequent (74%) but lacked strong associations with most clinicopathological variables. Although ATRX, Rb, and combined IHC patterns did not significantly stratify overall survival (OS), disease-free survival (DFS), or disease-specific survival (DSS), FNCLCC grade robustly differentiated outcomes, particularly for DFS (p = 0.000741) and DSS (p = 0.0206), with a clear trend in OS (p = 0.0711). Low-grade tumors exhibited no metastases and favorable survival. These findings validate FNCLCC grading as a cornerstone prognostic tool and demonstrate that ATRX IHC identifies clinically relevant subsets with aggressive local features. The observed discordance between IHC and genomic classifiers underscores the complexity of translating molecular alterations to protein-level surrogates, likely due to regulatory mechanisms beyond mutation. This work provides practical insights for risk assessment in STLMS and supports the integration of traditional grading with targeted IHC and molecular profiling for refined patient management.
Indexed as
Identifiers
42536169What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.